Fundraising Fox

Eyconis

Redwood City, US · Founded 2023 · Delaware corporation · 4 known investors

eyconis.com ↗

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

BiotechDigital HealthMedical Devicesin /eyconis-inc

Founders & leadership

EC
Emmett CunninghamExecutive Officer, Director
MB
Mark BachledaExecutive Officer, Director
RV
Robert VittiExecutive Officer
DE
Dan EstesDirector
AC
Anna ChenDirector
OS
Oliver StauchExecutive Officer
JM
Jan Moller MikkelsenDirector
DE
Daniel EstesExecutive Officer, Director, Promoter
OB
Oliver Boris StauchExecutive Officer
GE
Gordon EmpeyExecutive Officer, Promoter
CW
Conrad WangDirector
YY
Yvonne YamanakaDirector

Investors · 4

Frazier Life Sciences✓ verifiedPalo Alto
HealthQuest Capital✓ verifiedRedwood City
venBio Partners✓ verifiedSan Francisco
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements
▶$25MraisedOct 2025 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Conrad WangDirector
  • Yvonne YamanakaDirector
  • Emmett CunninghamExecutive Officer, Director
  • Mark BachledaExecutive Officer, Director
  • Robert VittiExecutive Officer
  • Dan EstesDirector
  • Anna ChenDirector
  • Oliver StauchExecutive Officer
  • Jan Moller MikkelsenDirector
Offering amount
$89.8M
Amount sold
$25M
First sale
Oct 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60.3MraisedFeb 2024 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel EstesExecutive Officer, Director, Promoter
  • Oliver Boris StauchExecutive Officer
  • Emmett CunninghamExecutive Officer, Director, Promoter
  • Jan Moller MikkelsenDirector
  • Gordon EmpeyExecutive Officer, Promoter
  • Conrad WangDirector
  • Yvonne YamanakaDirector
  • Anna ChenExecutive Officer, Director, Promoter
Offering amount
$150M
Amount sold
$60.3M
First sale
Jan 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.